Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Express Scripts
McKesson
Boehringer Ingelheim
Harvard Business School
Medtronic
Dow

Last Updated: January 30, 2023

Romiplostim - Biologic Drug Details


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Summary for romiplostim
Tradenames:1
Patents:4
Applicants:1
BLAs:1
Suppliers: see list1
Recent Clinical Trials: See clinical trials for romiplostim
Recent Clinical Trials for romiplostim

Identify potential brand extensions & biosimilar entrants

SponsorPhase
Peking University People's HospitalPhase 2
Fundación Pública Andaluza para la gestión de la Investigación en SevillaPhase 3
GeropharmPhase 1

See all romiplostim clinical trials

Pharmacology for romiplostim
Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

  1. Brand-side disclosures in response to biosimilar applications
  2. These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

  3. General brand-side disclosures
  4. These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

  5. Patents from broad patent text search
  6. For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for romiplostim Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for romiplostim Derived from Company Disclosures

These patents were obtained from company disclosures
Applicant Tradename Biologic Ingredient Dosage Form BLA Patent No. Estimated Patent Expiration Source
Amgen, Inc. NPLATE romiplostim For Injection 125268 See Plans and Pricing 2018-10-23 Company disclosures
Amgen, Inc. NPLATE romiplostim For Injection 125268 See Plans and Pricing 2018-10-23 Company disclosures
Amgen, Inc. NPLATE romiplostim For Injection 125268 See Plans and Pricing 2018-10-23 Company disclosures
Amgen, Inc. NPLATE romiplostim For Injection 125268 See Plans and Pricing 2018-10-23 Company disclosures
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Patent No. >Estimated Patent Expiration >Source

3) Low Certainty: US Patents for romiplostim Derived from Patent Text Search

These patents were obtained by searching patent claims

International Patents for romiplostim

Country Patent Number Estimated Expiration
Mexico PA01003873 See Plans and Pricing
World Intellectual Property Organization (WIPO) 0024782 See Plans and Pricing
China 1331701 See Plans and Pricing
Slovakia 4962001 See Plans and Pricing
Japan 2007105044 See Plans and Pricing
World Intellectual Property Organization (WIPO) 0024770 See Plans and Pricing
>Country >Patent Number >Estimated Expiration

Supplementary Protection Certificates for romiplostim

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
SZ 25/2009 Austria See Plans and Pricing PRODUCT NAME: ROMIPLOSTIM
CA 2009 00025 Denmark See Plans and Pricing
C200900026 Spain See Plans and Pricing PRODUCT NAME: ROMIPLOSTIM; NATIONAL AUTHORISATION NUMBER: 1/08/497/001-002; DATE OF AUTHORISATION: 20090204; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): UEEU/1/08/497/001-002; DATE OF FIRST AUTHORISATION IN EEA: 20090204
PA2009006 Lithuania See Plans and Pricing PRODUCT NAME: ROMIPLOSTIMUM; REGISTRATION NO/DATE: EU/1/08/497/001-002 20090204
SPC/GB09/035 United Kingdom See Plans and Pricing PRODUCT NAME: ROMIPLOSTIM; REGISTERED: UK EU/1/08/497/001 20090206; UK EU/1/08/497/002 20090206
25/2009 Austria See Plans and Pricing PRODUCT NAME: ROMIPLOSTIM; REGISTRATION NO/DATE: EU/1/08/497/001-002 20090204
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Moodys
McKesson
Dow
Merck
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.